Trial Profile
Characteristics and Risk Factor Burden of Patients Receiving Lipid Modifying Therapy in the United Kingdom
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 23 Oct 2017
Price :
$35
*
At a glance
- Drugs Ezetimibe (Primary)
- Indications Acute coronary syndromes
- Focus Therapeutic Use
- 08 Nov 2017 Results presented at the 20th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
- 23 Oct 2017 New trial record